HUP0500039A2 - Vakcina és eljárás mozgatóneuron-betegségek kezelésére - Google Patents

Vakcina és eljárás mozgatóneuron-betegségek kezelésére

Info

Publication number
HUP0500039A2
HUP0500039A2 HU0500039A HUP0500039A HUP0500039A2 HU P0500039 A2 HUP0500039 A2 HU P0500039A2 HU 0500039 A HU0500039 A HU 0500039A HU P0500039 A HUP0500039 A HU P0500039A HU P0500039 A2 HUP0500039 A2 HU P0500039A2
Authority
HU
Hungary
Prior art keywords
vaccine
treatment
cop
motor neurone
active ingredients
Prior art date
Application number
HU0500039A
Other languages
English (en)
Inventor
Michal Eisenbach-Schwartz
Esther Yoles
Original Assignee
Yeda Research And Development Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co., Ltd. filed Critical Yeda Research And Development Co., Ltd.
Publication of HUP0500039A2 publication Critical patent/HUP0500039A2/hu
Publication of HUP0500039A3 publication Critical patent/HUP0500039A3/hu
Publication of HU228207B1 publication Critical patent/HU228207B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány mozgatóneuron-betegségben (MND), különösen amiotrófiáslaterális szklerózisban szenvedő betegben a betegség súlyosbodásaés/vagy mozgatóideg-degeneráció és/vagy glutaminsav-toxicitás ellenivédelemre szolgáló vakcinára vonatkozik. A vakcina hatóanyagként Cop1-t, Cop 1-rokon peptidet, egy Cop 1-rokon polipeptidet vagy poli-G1u,Tyr-t tartalmaz, mely adjuvánssal vagy adjuváns nélkül adható be.A találmány a fenti hatóanyagok alkalmazására is vonatkozik vakcinaelőállítására. Ó
HU0500039A 2001-12-06 2002-12-05 Vakcina és eljárás mozgatóneuron-betegségek kezelésére HU228207B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06
PCT/IL2002/000979 WO2003047500A2 (en) 2001-12-06 2002-12-05 Vaccine and method for treatment of motor neurone diseases

Publications (3)

Publication Number Publication Date
HUP0500039A2 true HUP0500039A2 (hu) 2005-03-29
HUP0500039A3 HUP0500039A3 (en) 2010-01-28
HU228207B1 HU228207B1 (hu) 2013-01-28

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500039A HU228207B1 (hu) 2001-12-06 2002-12-05 Vakcina és eljárás mozgatóneuron-betegségek kezelésére

Country Status (24)

Country Link
US (1) US7351686B2 (hu)
EP (1) EP1429800B1 (hu)
JP (1) JP4542339B2 (hu)
KR (1) KR20040081431A (hu)
CN (2) CN1617736A (hu)
AT (1) ATE422362T1 (hu)
AU (1) AU2002353486B2 (hu)
CA (1) CA2469092C (hu)
CY (1) CY1109044T1 (hu)
DE (1) DE60231131D1 (hu)
DK (1) DK1429800T3 (hu)
ES (1) ES2322566T3 (hu)
HK (1) HK1067043A1 (hu)
HU (1) HU228207B1 (hu)
IL (1) IL160105A0 (hu)
IS (1) IS2670B (hu)
MX (1) MXPA04005537A (hu)
NO (1) NO336231B1 (hu)
NZ (1) NZ533356A (hu)
PL (1) PL205469B1 (hu)
PT (1) PT1429800E (hu)
RU (1) RU2303996C2 (hu)
SI (1) SI1429800T1 (hu)
WO (1) WO2003047500A2 (hu)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
MXPA05007329A (es) * 2003-01-07 2005-09-30 Yeda Res & Dev Vacuna de gotas oculares que contiene copolimero 1 para inmunizacion terapeutica.
JP5456235B2 (ja) 2003-11-12 2014-03-26 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経変性疾患を治療するためのワクチン及び方法
EP1701730B1 (en) 2003-12-09 2013-08-21 Yeda Research And Development Co., Ltd. Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders
AU2005218625A1 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
NZ551236A (en) * 2004-05-07 2010-11-26 Peptimmune Inc Methods of treating disease with random copolymers
JP5241012B2 (ja) * 2005-07-15 2013-07-17 ノバルティス アーゲー Ｐａｍｐｓ、病原体関連分子パターン
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
WO2009040814A1 (en) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
MX347871B (es) 2010-10-11 2017-05-16 Teva Pharmaceutical Ind Ltd * Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
WO2013084236A1 (en) * 2011-12-05 2013-06-13 Ben-Gurion University Of The Negev Research And Development Authority Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (als)
EP2831584B1 (en) * 2012-03-26 2020-06-17 Yeda Research and Development Co., Ltd. Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression
EP3320914B1 (en) 2012-09-10 2020-12-30 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science T-helper 1 adjuvant for treating amyotrophic lateral sclerosis
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
SE505316C2 (sv) 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
WO1999034827A1 (en) 1998-07-21 1999-07-15 Yeda Research And Development Co. Ltd. Activated t-cells and their uses
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20030108528A1 (en) 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
CA2328612A1 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
AU766498B2 (en) 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
WO2001093893A2 (en) * 2000-06-07 2001-12-13 Yeda Research And Development Co. Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy

Also Published As

Publication number Publication date
CA2469092C (en) 2013-02-19
US7351686B2 (en) 2008-04-01
SI1429800T1 (sl) 2009-08-31
PT1429800E (pt) 2009-04-27
DK1429800T3 (da) 2009-04-27
WO2003047500A3 (en) 2004-03-18
CY1109044T1 (el) 2014-07-02
AU2002353486B2 (en) 2009-01-15
PL205469B1 (pl) 2010-04-30
JP4542339B2 (ja) 2010-09-15
IS2670B (is) 2010-09-15
RU2303996C2 (ru) 2007-08-10
AU2002353486A1 (en) 2003-06-17
CN102151330B (zh) 2017-04-12
NZ533356A (en) 2006-10-27
CA2469092A1 (en) 2003-06-12
ES2322566T3 (es) 2009-06-23
EP1429800B1 (en) 2009-02-11
HK1067043A1 (en) 2005-04-01
NO20042833L (no) 2004-08-12
HU228207B1 (hu) 2013-01-28
JP2005515198A (ja) 2005-05-26
CN102151330A (zh) 2011-08-17
IL160105A0 (en) 2004-06-20
ATE422362T1 (de) 2009-02-15
EP1429800A2 (en) 2004-06-23
EP1429800A4 (en) 2006-03-22
WO2003047500A2 (en) 2003-06-12
HUP0500039A3 (en) 2010-01-28
NO336231B1 (no) 2015-06-22
KR20040081431A (ko) 2004-09-21
RU2004120536A (ru) 2005-03-27
MXPA04005537A (es) 2004-11-01
IS7296A (is) 2004-06-03
DE60231131D1 (de) 2009-03-26
PL370070A1 (en) 2005-05-16
CN1617736A (zh) 2005-05-18
US20050220802A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
HUP0500039A2 (hu) Vakcina és eljárás mozgatóneuron-betegségek kezelésére
NO20053855D0 (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
HUP0204123A2 (hu) Készítmények meghűlés és influenzaszerű tünetek megelőzésére és kezelésére, előállításuk és alkalmazásuk
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
HUP0303143A2 (hu) A VII-es faktor és a IX-es faktor polipeptidek kombinált alkalmazása
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
NO20083958L (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
MA27699A1 (fr) Vaccin contre vhc
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
HUP0302636A2 (hu) Hasított burkolt víruskészítmény
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2003055440A3 (en) Compositions and methods for the treatement of immune related diseases
HUP0400737A2 (hu) L-karnitin alkalmazása proteinek stabilizálására szolgáló készítmények előállítására
HUP0300787A2 (hu) Új interferon a sclerosis multiplex kezelésére
DE60223564D1 (de) Therapeutische impfzusammensetzung zur verhütung und behandlung von erkrankungen bei säugetieren
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
WO2004004649A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002062976A3 (en) Serine proteases

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees